Anti-CD3 Antibody Treatment Induces Hypoglycemia and Super Tolerance to Glucose Challenge in Mice through Enhancing Glucose Consumption by Activated Lymphocytes

Anti-CD3 antibody has been employed for various immune-mediated disorders. However, whether anti-CD3 administration leads to rapid metabolic alternation has not been well investigated. In the current study, we studied how anti-CD3 treatment affected blood glucose levels in mice. We found that anti-C...

Full description

Saved in:
Bibliographic Details
Main Authors: Chang-Qing Xia, Anna V. Chernatynskaya, Benjamin Looney, Suigui Wan, Michael J. Clare-Salzler
Format: Article
Language:English
Published: Wiley 2014-01-01
Series:Journal of Immunology Research
Online Access:http://dx.doi.org/10.1155/2014/326708
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850176415346982912
author Chang-Qing Xia
Anna V. Chernatynskaya
Benjamin Looney
Suigui Wan
Michael J. Clare-Salzler
author_facet Chang-Qing Xia
Anna V. Chernatynskaya
Benjamin Looney
Suigui Wan
Michael J. Clare-Salzler
author_sort Chang-Qing Xia
collection DOAJ
description Anti-CD3 antibody has been employed for various immune-mediated disorders. However, whether anti-CD3 administration leads to rapid metabolic alternation has not been well investigated. In the current study, we studied how anti-CD3 treatment affected blood glucose levels in mice. We found that anti-CD3 treatment induced immediate reduction of blood glucose after administration. Furthermore, a single dose of anti-CD3 treatment corrected hyperglycemia in all nonobese diabetic mice with recently diagnosed diabetes. This glucose-lowering effect was not attributable to major T cell produced cytokines. Of interest, when tested in a normal strain of mice (C57BL/6), the serum levels of C-peptide in anti-CD3 treated animals were significantly lower than control mice. Paradoxically, anti-CD3 treated animals were highly tolerant to exogenous glucose challenge. Additionally, we found that anti-CD3 treatment significantly induced activation of T and B cells in vitro and in vivo. Further studies demonstrated that anti-CD3 treatment lowered the glucose levels in T cell culture media and increased the intracellular transportation of 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2 deoxyglucose (2-NBDG) particularly in activated T and B cells. In addition, injection of anti-CD3 antibodies induced enhanced levels of Glut1 expression in spleen cells. This study suggests that anti-CD3 therapy-induced hypoglycemia likely results from increased glucose transportation and consumption by the activated lymphocytes.
format Article
id doaj-art-af13728358d44b27835400b2e8a9ff3c
institution OA Journals
issn 2314-8861
2314-7156
language English
publishDate 2014-01-01
publisher Wiley
record_format Article
series Journal of Immunology Research
spelling doaj-art-af13728358d44b27835400b2e8a9ff3c2025-08-20T02:19:16ZengWileyJournal of Immunology Research2314-88612314-71562014-01-01201410.1155/2014/326708326708Anti-CD3 Antibody Treatment Induces Hypoglycemia and Super Tolerance to Glucose Challenge in Mice through Enhancing Glucose Consumption by Activated LymphocytesChang-Qing Xia0Anna V. Chernatynskaya1Benjamin Looney2Suigui Wan3Michael J. Clare-Salzler4Department of Hematology, Xuanwu Hospital, Capital Medical University, No. 45 Changchun Street, Xicheng District, Beijing 100053, ChinaDepartment of Pathology, Immunology and Laboratory Medicine, University of Florida College of Medicine, Gainesville, FL 32610, USADepartment of Pathology, Immunology and Laboratory Medicine, University of Florida College of Medicine, Gainesville, FL 32610, USADepartment of Hematology, Xuanwu Hospital, Capital Medical University, No. 45 Changchun Street, Xicheng District, Beijing 100053, ChinaDepartment of Pathology, Immunology and Laboratory Medicine, University of Florida College of Medicine, Gainesville, FL 32610, USAAnti-CD3 antibody has been employed for various immune-mediated disorders. However, whether anti-CD3 administration leads to rapid metabolic alternation has not been well investigated. In the current study, we studied how anti-CD3 treatment affected blood glucose levels in mice. We found that anti-CD3 treatment induced immediate reduction of blood glucose after administration. Furthermore, a single dose of anti-CD3 treatment corrected hyperglycemia in all nonobese diabetic mice with recently diagnosed diabetes. This glucose-lowering effect was not attributable to major T cell produced cytokines. Of interest, when tested in a normal strain of mice (C57BL/6), the serum levels of C-peptide in anti-CD3 treated animals were significantly lower than control mice. Paradoxically, anti-CD3 treated animals were highly tolerant to exogenous glucose challenge. Additionally, we found that anti-CD3 treatment significantly induced activation of T and B cells in vitro and in vivo. Further studies demonstrated that anti-CD3 treatment lowered the glucose levels in T cell culture media and increased the intracellular transportation of 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2 deoxyglucose (2-NBDG) particularly in activated T and B cells. In addition, injection of anti-CD3 antibodies induced enhanced levels of Glut1 expression in spleen cells. This study suggests that anti-CD3 therapy-induced hypoglycemia likely results from increased glucose transportation and consumption by the activated lymphocytes.http://dx.doi.org/10.1155/2014/326708
spellingShingle Chang-Qing Xia
Anna V. Chernatynskaya
Benjamin Looney
Suigui Wan
Michael J. Clare-Salzler
Anti-CD3 Antibody Treatment Induces Hypoglycemia and Super Tolerance to Glucose Challenge in Mice through Enhancing Glucose Consumption by Activated Lymphocytes
Journal of Immunology Research
title Anti-CD3 Antibody Treatment Induces Hypoglycemia and Super Tolerance to Glucose Challenge in Mice through Enhancing Glucose Consumption by Activated Lymphocytes
title_full Anti-CD3 Antibody Treatment Induces Hypoglycemia and Super Tolerance to Glucose Challenge in Mice through Enhancing Glucose Consumption by Activated Lymphocytes
title_fullStr Anti-CD3 Antibody Treatment Induces Hypoglycemia and Super Tolerance to Glucose Challenge in Mice through Enhancing Glucose Consumption by Activated Lymphocytes
title_full_unstemmed Anti-CD3 Antibody Treatment Induces Hypoglycemia and Super Tolerance to Glucose Challenge in Mice through Enhancing Glucose Consumption by Activated Lymphocytes
title_short Anti-CD3 Antibody Treatment Induces Hypoglycemia and Super Tolerance to Glucose Challenge in Mice through Enhancing Glucose Consumption by Activated Lymphocytes
title_sort anti cd3 antibody treatment induces hypoglycemia and super tolerance to glucose challenge in mice through enhancing glucose consumption by activated lymphocytes
url http://dx.doi.org/10.1155/2014/326708
work_keys_str_mv AT changqingxia anticd3antibodytreatmentinduceshypoglycemiaandsupertolerancetoglucosechallengeinmicethroughenhancingglucoseconsumptionbyactivatedlymphocytes
AT annavchernatynskaya anticd3antibodytreatmentinduceshypoglycemiaandsupertolerancetoglucosechallengeinmicethroughenhancingglucoseconsumptionbyactivatedlymphocytes
AT benjaminlooney anticd3antibodytreatmentinduceshypoglycemiaandsupertolerancetoglucosechallengeinmicethroughenhancingglucoseconsumptionbyactivatedlymphocytes
AT suiguiwan anticd3antibodytreatmentinduceshypoglycemiaandsupertolerancetoglucosechallengeinmicethroughenhancingglucoseconsumptionbyactivatedlymphocytes
AT michaeljclaresalzler anticd3antibodytreatmentinduceshypoglycemiaandsupertolerancetoglucosechallengeinmicethroughenhancingglucoseconsumptionbyactivatedlymphocytes